Member Posts > A New Chapter in Heart Failure Treatment? Cardiol Therapeutics' CRD-38 Shows Strong Pre-Clinical Data
Cardiol Therapeutics is taking a major step forward in cardiovascular research, as CRD-38 demonstrates powerful cardioprotective effects in pre-clinical trials. The latest findings, published in The Journal of the American College of Cardiology: Basic to Translational Science, highlight the drug's ability to improve heart function, reduce inflammation, and maintain structural integrity.
Major Findings
• Stronger Heart Performance: CRD-38 enhances cardiac output and contractility.
• Reduction in Structural Damage: The therapy prevents heart muscle thickening and fibrosis.
• Anti-Inflammatory Impact: CRD-38 significantly lowers pro-inflammatory cytokines, key contributors to HFpEF.
• Cellular Energy Support: The drug protects mitochondrial function, vital for sustained cardiac function.
The Future of CRD-38
Cardiol Therapeutics is now preparing for clinical trials, marking a significant milestone in its mission to provide a groundbreaking treatment for HFpEF patients.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs